Recent Updates
Recently added Catalysts
EXOZ Positive Sentiment

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

Wednesday, June 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: eXoZymes Inc. has received a $2 million grant from the NIH to advance its cannabinoid analogs for drug discovery. This funding will support the company's efforts to develop new pharmaceutical assets and validate its capabilities in producing rare cannabinoids. The project is set to commence on July 1, 2026, marking a significant step in eXoZymes' growth.
Price reaction · baseline $7.14 (2026-06-24 close) · hit after-hours · 4 other EXOZ headline(s) in the window, move may be shared
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • eXoZymes awarded a significant $2 million NIH grant.
  • The grant validates the company's ability to produce rare cannabinoids.
  • Total non-dilutive funding for eXoZymes now approaches $20 million.
  • The project supports the expansion of their pharmaceutical portfolio.

Full Press Release Details

• Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company’s ability to make rare cannabinoids and new cannabinoid-like molecules.
• NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.
• Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company’s platform
LOS ANGELES, CA -- June 24, 2026 -- eXoZymes Inc. (NASDAQ: EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals - today announced that it has received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518.

Frequently Asked Questions

What is the purpose of the NIH grant awarded to eXoZymes?

The NIH grant aims to advance eXoZymes' cannabinoid analogs for drug discovery.

How much funding did eXoZymes receive from the NIH?

eXoZymes received a total of $2,028,518 from the NIH.

When will the NIH-backed project for eXoZymes start?

The project is expected to begin on July 1, 2026.

What is the total non-dilutive funding for eXoZymes now?

The total non-dilutive funding awarded to eXoZymes is nearly $20 million.

ShareAdd on Google
Tags: EXOZ Viatris Investor Conferences Healthcare eXoZymes NIH grant cannabinoid analogs drug discovery pharmaceutical assets
Last updated: Jun 24, 2026

Biotech snapshot

Cash runway
$6M liquidity · $1M/mo burn
~10 mo
Medium dilution risk